Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirena versus oral medroxyprogesterone acetate for non-atypical endometrial hyperplasia
CTR20260808Phase 3Terminated
- Sponsor
- Bayer Yakuhin
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of avatrombopag, medroxyprogesterone acetate in Endometrial Hyperplasia Without Atypia (EH), sponsored by Bayer Yakuhin. Started Mar 2026; status: terminated.
02
Drugs
avatrombopagmedroxyprogesterone acetate
03
Conditions
Endometrial Hyperplasia Without Atypia (EH)
Beyond the preview
Go deeper on CTR20260808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260808.